کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2171218 1093473 2015 10 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Intravenous infusion of allogeneic mesenchymal stromal cells in refractory or relapsed aplastic anemia
ترجمه فارسی عنوان
تزریق داخل وریدی سلول های استرومائین مزانشیمی آلوژنیک در کمخونی آپلاستیک پدید می آید
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی بیولوژی سلول
چکیده انگلیسی

Background aimsFor patients with aplastic anemia (AA) who are refractory to anti-thymocyte globulin (ATG) and cyclosporine, a second course of immunosuppression is successful in only one-fourth to one-third of cases.MethodsWe conducted a phase 1/2 study to evaluate the addition of two to five weekly intravenous infusions of allogeneic unrelated non–human leukocyte antigen–matched bone marrow–derived mesenchymal stromal cells (MSCs) (median, 2.7 × 106 cells/kg/infusion; range, 1.3–4.5) to standard rabbit ATG and cyclosporine in nine patients with refractory or relapsed AA.ResultsAfter a median follow-up of 20 months, no infusion-related adverse event was observed, but four deaths occurred as the result of heart failure and bacterial or invasive fungal infections; only two patients achieved partial hematologic responses at 6 months. We failed to demonstrate by fluorescence in situ hybridization or variable number tandem repeat any MSC engraftment in patient marrow 30, 90 or 180 days after infusions.ConclusionsInfusion of allogeneic MSCs in AA is safe but does not improve clinical hematologic response or engraft in recipient bone marrow. This study was registered at clinicaltrials.gov, identifier: NCT01297972.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cytotherapy - Volume 17, Issue 12, December 2015, Pages 1696–1705
نویسندگان
, , , , , , ,